Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Anbio Biotechnology's Enterprise Value is $534.98 Mil.
Anbio Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil. Therefore, Anbio Biotechnology's EV-to-EBIT ratio for today is 92.77.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Anbio Biotechnology's Enterprise Value is $534.98 Mil.
Anbio Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil. Therefore, Anbio Biotechnology's EV-to-EBITDA ratio for today is 92.77.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Anbio Biotechnology's Enterprise Value is $534.98 Mil.
Anbio Biotechnology's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $8.65 Mil. Therefore, Anbio Biotechnology's EV-to-Revenue ratio for today is 61.87.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Anbio Biotechnology (NAS:NNNN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Anbio Biotechnology's current Enterprise Value is $534.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Anbio Biotechnology's current Enterprise Value is $534.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil.
Anbio Biotechnology's current Enterprise Value is $534.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $8.65 Mil.
Anbio Biotechnology's current Enterprise Value is $534.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $1.48 Mil.
Anbio Biotechnology's current Enterprise Value is $534.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $1.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology Enterprise Value Related Terms
Anbio Biotechnology Enterprise Value Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Anbio Biotechnology's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a Enterprise Value of $534.98 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Anbio Biotechnology and its competitors.
Is Anbio Biotechnology's Enterprise Value too high?
Anbio Biotechnology's current Enterprise Value is $534.98 Mil. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Enterprise Value compare to ANGO and OSUR?
Anbio Biotechnology's Enterprise Value of $534.98 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Anbio Biotechnology and its competitors. Anbio Biotechnology's current Enterprise Value is $534.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Enterprise Value of $534.98 Mil. The current Enterprise Value is $534.98 Mil. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Enterprise Value is $534.98 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
